Corrigendum through General Announcement regarding disclosure of Pre-Preferential Shareholding of Proposed Allottees, Ultimate Beneficial Owners (UBOs), Revised Issue Size of Proposed Preferential ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals has issued a corrigendum to its earlier preferential issue disclosures, updating the list of allottees, Ultimate Beneficial Owners (UBOs), and issue size. The revised issue comprises 6,44,360 equity shares to non-promoters and 5,51,600 convertible warrants (2,00,000 to promoter group, 3,51,600 to non-promoters), taking the post-issue paid-up capital to Rs. 5,91,76,220 from Rs. 4,72,16,620. Total estimated fund utilisation is around Rs. 153.25 crores, with 35% earmarked for Brand Marketing & Distribution and 35% for Working Capital, followed by Strategic Reserves (15%), CAPEX (5%), R&D (5%), and Contingency (5%). The funds will support expansion into Pet Care, Human Nutraceuticals/Cosmeceuticals, and Pharma Generics, with initial focus on markets like Sri Lanka, UAE, Nigeria, and the Philippines. Notable allottees include Alchemy Capital Management (linked to the Jhunjhunwala family estate), the Jaisinghani family (R R Family Trust), NAV Capital funds, and Capri Global Holdings.
The preferential allotment will dilute existing shareholders but brings in several well-known investor names, lending credibility to the expansion plan. The Rs. 153+ crore raise supports ambitious growth into new verticals and geographies, though execution risk is significant given the small current capital base (paid-up equity of ~Rs. 4.7 crores) relative to the planned deployment.